Article Information
- Received August 6, 2019
- Accepted September 18, 2019
- First published November 4, 2019.
- Version of record published December 4, 2019.
Author Information
- Esi Domi1,3,
- Francesca Felicia Caputi2,
- Patrizia Romualdi2,
- Ana Domi1,
- Giulia Scuppa1,
- Sanzio Candeletti2,
- Alison Atkins3,
- Markus Heilig3,
- Gregory Demopulos4,
- George Gaitanaris4,
- Roberto Ciccocioppo1,*, and
- Massimo Ubaldi1,*
- 1School of Pharmacy, Pharmacology Unit, University of Camerino, Camerino 62032, Italy,
- 2Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Bologna, 40126 Italy,
- 3Center for Social and Affective Neuroscience, IKE, Linköping University, Linköping, 58183, Sweden, and
- 4Omeros Corporation, Seattle, Washington 98101
Author contributions
Author contributions: E.D., P.R., S.C., M.H., R.C., and M.U. designed research; E.D., F.F.C., A.D., G.S., A.A., and M.U. performed research; E.D., F.F.C., A.D., G.S., S.C., A.A., G.D., G.G., R.C., and M.U. analyzed data; E.D., F.F.C., and M.U. wrote the paper.
↵*R.C. and M.U. contributed equally to this work.
Disclosures
- Received August 6, 2019.
- Accepted September 18, 2019.
This work was supported by a fellowship (to E.D.) from the Italian Society of Pharmacology, and by NIH Grants RO1 AA017447 and AA014351, and Grant PRIN 2017 (2017SXEXT5) to R.C. We thank Dr. Kevin Niswender at Vanderbild University (Nashville, TN) for providing the PPARγ engineered mouse lines, Serena Stopponi for animal care supervision, and Alfredo Fiorelli for technical support.
G.D. is the Chairman and CEO of Omeros, G.G. is Chief Scientific Officer of Omeros, and R.C. is the inventor on several patent applications relating to the therapeutic use of PPARγ agonists in addiction. Omeros, through agreements with the University of Camerino and with R.C., exclusively controls the intellectual property rights directed to R.C.'s inventions related to the use of PPARγ receptor agonists for the treatment of addiction and addictive behaviors. Under these agreements, R.C. may be entitled to receive payments and royalties from Omeros. The remaining authors declare no competing financial interests.
- Correspondence should be addressed to Roberto Ciccocioppo at roberto.ciccocioppo{at}unicam.it
Other Version
- previous version (November 04, 2019).
- You are viewing the most recent version of this article.
Online Impact